Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Biliary Tract Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 123 articles:
HTML format



Single Articles


    July 2022
  1. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    PubMed    


  2. ZHANG R, Su L, Fu M, Wang Z, et al
    CD177(+) cells produce neutrophil extracellular traps to promote biliary atresia.
    J Hepatol. 2022 Jul 5. pii: S0168-8278(22)00409.
    PubMed     Abstract available


  3. MULLER AL, Casar C, Preti M, Krzikalla D, et al
    Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02923.
    PubMed     Abstract available


    June 2022
  4. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    PubMed     Abstract available


  5. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    PubMed     Abstract available


  6. LABIANO I, Agirre-Lizaso A, Olaizola P, Echebarria A, et al
    TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.
    J Hepatol. 2022 Jun 21. pii: S0168-8278(22)00372.
    PubMed     Abstract available


  7. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    PubMed     Abstract available


  8. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    PubMed    


  9. HOGDALL D, O'Rourke CJ, Larsen FO, Zarforoushan S, et al
    Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00358.
    PubMed     Abstract available


  10. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    PubMed    


  11. SCHLEGEL A, Porte R, Dutkowski P
    Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy.
    J Hepatol. 2022;76:1330-1347.
    PubMed     Abstract available


    May 2022

  12. EASL Clinical Practice Guidelines on Sclerosing Cholangitis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00326.
    PubMed    


  13. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    PubMed    


  14. RAGGI C, Taddei ML, Rae C, Braconi C, et al
    Metabolic Reprogramming in Cholangiocarcinoma.
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00314.
    PubMed     Abstract available


  15. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    PubMed    


    April 2022
  16. LUDDE T, Boulter L
    Joining the dots - NEDDylation in cancer cells regulates the tumour environment in Cholangiocarcinoma.
    J Hepatol. 2022 Apr 28. pii: S0168-8278(22)00253.
    PubMed    


    March 2022
  17. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    PubMed     Abstract available


  18. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    PubMed     Abstract available


  19. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    PubMed    


    February 2022
  20. OLAIZOLA P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, et al
    Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00082.
    PubMed     Abstract available


  21. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    PubMed     Abstract available


    January 2022
  22. CASOLINO R, Amato F, Rae C, Puttagunta S, et al
    Receptor Tyrosine kinase co-amplification and benefit from HER2 inhibitors in Biliary Tract Cancers.
    J Hepatol. 2022 Jan 27. pii: S0168-8278(22)00025.
    PubMed    


    December 2021
  23. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    PubMed     Abstract available


  24. IZQUIERDO-SANCHEZ L, Lamarca A, La Casta A, Buettner S, et al
    Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02252.
    PubMed     Abstract available


  25. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    PubMed    


    November 2021
  26. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    PubMed     Abstract available


    October 2021
  27. HERTA T, Kersten R, Chang JC, Hubers L, et al
    Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection.
    J Hepatol. 2021 Oct 27. pii: S0168-8278(21)02116.
    PubMed     Abstract available


  28. KEPPLER D, Beuers U, Trauner M
    A life with bile acids: Alan F. Hofmann (1931-2021).
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02081.
    PubMed    


  29. LOUIS C, Coulouarn C
    One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/beta-catenin pathways in cholangiocarcinoma.
    J Hepatol. 2021 Oct 12. pii: S0168-8278(21)02108.
    PubMed    


  30. MALLET V
    Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".
    J Hepatol. 2021;75:990-992.
    PubMed    


    September 2021
  31. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    PubMed     Abstract available


  32. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    PubMed     Abstract available


    August 2021
  33. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
    New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
    J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
    PubMed    


  34. DE JONG IEM, van den Heuvel MC, Wells RG, Porte RJ, et al
    The heterogeneity of the biliary tree.
    J Hepatol. 2021 Aug 19. pii: S0168-8278(21)00251.
    PubMed    


    July 2021
  35. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    PubMed     Abstract available


  36. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
    AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
    PubMed    


  37. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    PubMed    


    June 2021
  38. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available


  39. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    PubMed    


  40. ZHANG Y, Zuo C, Liu L, Hu Y, et al
    Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00442.
    PubMed     Abstract available


  41. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    PubMed    


  42. WEI G, Cao J, Huang P, An P, et al
    Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
    J Hepatol. 2021;74:1416-1428.
    PubMed     Abstract available


    May 2021
  43. SONG X, Xu H, Wang P, Wang J, et al
    Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00353.
    PubMed     Abstract available


  44. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    PubMed     Abstract available


  45. BOULTER L, Ebrahimkhani MR
    Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
    J Hepatol. 2021 May 21. pii: S0168-8278(21)00341.
    PubMed    


  46. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    PubMed    


  47. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available


    April 2021
  48. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    PubMed     Abstract available


  49. REICH M, Spomer L, Klindt C, Fuchs K, et al
    Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00244.
    PubMed     Abstract available


  50. VALLEJO A, Erice O, Entrialgo-Cadierno R, Feliu I, et al
    FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
    J Hepatol. 2021 Apr 14. pii: S0168-8278(21)00235.
    PubMed     Abstract available


    March 2021
  51. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available


  52. DELTENRE P, Moreno C, Trepo E
    Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
    J Hepatol. 2021 Mar 19. pii: S0168-8278(21)00179.
    PubMed    


  53. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    PubMed     Abstract available


  54. CRISTINZIANO G, Porru M, Lamberti D, Buglioni S, et al
    FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    J Hepatol. 2021 Mar 16. pii: S0168-8278(21)00172.
    PubMed     Abstract available


  55. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
    Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
    J Hepatol. 2021;74:593-602.
    PubMed     Abstract available


    February 2021
  56. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    PubMed    


  57. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    PubMed    


  58. BOYER JL, Soroka CJ
    Bile formation and Secretion: An update.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00111.
    PubMed     Abstract available


  59. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    PubMed    


  60. CASOLINO R, Braconi C
    CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00045.
    PubMed    


  61. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    PubMed    


  62. ROESSLER S, Edeline J, Schirmacher P, Coulouarn C, et al
    Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer.
    J Hepatol. 2021 Feb 16. pii: S0168-8278(21)00007.
    PubMed    


  63. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    PubMed    


  64. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available


  65. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    PubMed     Abstract available


    January 2021
  66. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    PubMed     Abstract available


  67. JAVITT NB
    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
    PubMed    


  68. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    PubMed     Abstract available


  69. RAGGI C, Taddei ML, Sacco E, Navari N, et al
    Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00024.
    PubMed     Abstract available


  70. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    PubMed     Abstract available


  71. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    PubMed    


  72. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    PubMed    


    December 2020
  73. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
    PubMed    


  74. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
    PubMed    


  75. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    PubMed     Abstract available


  76. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    PubMed     Abstract available


  77. NEPAL C, Zhu B, O'Rourke CJ, Bhatt DK, et al
    Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33820.
    PubMed     Abstract available


    November 2020
  78. DWYER BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, et al
    TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33771.
    PubMed     Abstract available


  79. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    PubMed     Abstract available


  80. STEIN S, Henze L, Poch T, Carambia A, et al
    IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33759.
    PubMed     Abstract available


    October 2020
  81. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    PubMed     Abstract available


  82. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    PubMed    


  83. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    PubMed    


  84. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    PubMed     Abstract available


    September 2020
  85. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    PubMed     Abstract available


  86. LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
    Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
    PubMed     Abstract available


  87. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.
    PubMed    


  88. BALAPHAS A, Gkoufa K, Meyer J, Peloso A, et al
    Covid-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30550.
    PubMed    


  89. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    PubMed    


    August 2020
  90. IZURIETA PACHECO AC, Monfort Carretero L, Prat Torres C, Garcia-Alix Perez A, et al
    NISCH syndrome: An extremely rare cause of neonatal cholestasis.
    J Hepatol. 2020 Aug 27. pii: S0168-8278(20)30459.
    PubMed    


    July 2020
  91. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    PubMed     Abstract available


  92. CARBONE M, Milani C, Gerussi A, Ronca V, et al
    Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30362.
    PubMed    


  93. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    PubMed    


  94. TRAUNER M
    Effective medical treatments for PSC needed ASAP - is AESOP the answer?
    J Hepatol. 2020;73:12-14.
    PubMed    


    June 2020
  95. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    PubMed     Abstract available


  96. BREVINI T, Tysoe OC, Sampaziotis F
    Tissue engineering of the biliary tract and modelling of cholestatic disorders.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30367.
    PubMed     Abstract available


  97. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    PubMed     Abstract available


  98. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    PubMed    


  99. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    PubMed    


    May 2020
  100. MCNAMARA MG, Lopes A, Wasan H, Malka D, et al
    Landmark survival analysis and impact of anatomic origin in prospective clinical trials of biliary tract cancer.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30306.
    PubMed     Abstract available


  101. JACKSON SS, Adami HO, Andreotti G, Beane-Freeman LE, et al
    Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30292.
    PubMed     Abstract available


  102. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    PubMed     Abstract available


    April 2020
  103. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    PubMed     Abstract available


  104. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    PubMed     Abstract available


    March 2020
  105. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.
    PubMed    


  106. JIANG M, Deng H, Liu S, Su S, et al
    Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis].
    J Hepatol. 2020 Mar 17. pii: S0168-8278(20)30067.
    PubMed    


  107. MONTAL R, Sia D, Montironi C, Leow WQ, et al
    Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Mar 12. pii: S0168-8278(20)30166.
    PubMed     Abstract available


  108. LAMARCA A, Barriuso J, McNamara MG, Valle JW, et al
    Molecular targeted therapies: ready for "prime time" in biliary tract cancer.
    J Hepatol. 2020 Mar 11. pii: S0168-8278(20)30165.
    PubMed     Abstract available


  109. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    PubMed     Abstract available


    February 2020
  110. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    PubMed     Abstract available


  111. MAZZAFERRO V, Gorgen A, Roayaie S, Droz Dit Busset M, et al
    Liver resection and transplantation for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:364-377.
    PubMed     Abstract available


  112. KELLEY RK, Bridgewater J, Gores GJ, Zhu AX, et al
    Systemic therapies for intrahepatic cholangiocarcinoma.
    J Hepatol. 2020;72:353-363.
    PubMed     Abstract available


    January 2020
  113. PANZITT K, Jungwirth E, Krones E, Lee JM, et al
    FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
    J Hepatol. 2020 Jan 27. pii: S0168-8278(20)30031.
    PubMed     Abstract available


    December 2019
  114. DE VRIES E, Beuers U
    Reply to: "UDCA therapy in intrahepatic cholestasis of pregnancy?"
    J Hepatol. 2019 Dec 28. pii: S0168-8278(19)30705.
    PubMed    


  115. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    PubMed     Abstract available


  116. KUMAR P, Kulkarni A
    UDCA therapy in intrahepatic cholestasis of pregnancy?
    J Hepatol. 2019 Dec 18. pii: S0168-8278(19)30653.
    PubMed    


  117. PEI T, Meng F, Xiao P, Han J, et al
    MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    J Hepatol. 2019 Dec 11. pii: S0168-8278(19)30713.
    PubMed     Abstract available


    October 2019
  118. MEUNIER L, Meszaros M, Pageaux GP, Larrey D, et al
    Potential role of ketamine in burn-associated cholestasis.
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30475.
    PubMed    


    September 2019
  119. LEGRAND M, de Tymowski C, Hodjat K, Mallet V, et al
    Reply to: "Potential role of ketamine in burn-associated cholestasis".
    J Hepatol. 2019 Sep 30. pii: S0168-8278(19)30542.
    PubMed    


  120. BERTUCCIO P, Malvezzi M, Carioli G, Hashim D, et al
    Reply to: "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma".
    J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30527.
    PubMed    


  121. KHANDEKAR G, Llewellyn J, Kriegermeier A, Waisbourd-Zinman O, et al
    Coordinated development of the mouse extrahepatic bile duct: implications for neonatal susceptibility to biliary injury.
    J Hepatol. 2019 Sep 25. pii: S0168-8278(19)30550.
    PubMed     Abstract available


  122. KHAN SA, Genus T, Morement H, Murphy A, et al
    Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.
    J Hepatol. 2019 Sep 23. pii: S0168-8278(19)30466.
    PubMed    


    February 2019
  123. VERGIS N, Atkinson SR, Thursz MR
    The future of therapy for alcoholic hepatitis - Beyond corticosteroids.
    J Hepatol. 2019 Feb 18. pii: S0168-8278(19)30030.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: